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Abstract
Background Alterations of dopamine  D1 (D1R) and  D2 receptor (D2R) are proposed in schizophrenia but brain neuroimaging 
and postmortem studies have shown controversial results in relation to D1R and D2R density. Besides, scarce information 
on the functionality of brain D1R and D2R is available. The present study characterized G-protein activation by D1R and 
D2R agonists in postmortem human brain. Furthermore, D2R functional status was compared between schizophrenia and 
control subjects.
Methods G-protein receptor coupling was assessed in control caudate nucleus and frontal cortex by  [35S]GTPγS-binding 
stimulation induced by increasing concentrations  (10–10–10–3 M) of dopamine, and the selective dopaminergic agonists 
SKF38393 (D1R) and NPA (D2R). Concentration–response curves to NPA stimulation of  [35S]GTPγS binding were ana-
lyzed in antipsychotic-free (n = 10) and antipsychotic-treated (n = 7) schizophrenia subjects and matched controls (n = 17).
Results In caudate,  [35S]GTPγS-binding responses to agonists were compatible with the existence of functional D2R. In 
contrast, stimulations in cortex showed responses that did not correspond to D1R or D2R.  [35S]GTPγS-binding activation 
by NPA in caudate displayed biphasic curves with similar profile in schizophrenia  (EC50H = 7.94 nM;  EC50L = 7.08 μM) and 
control  (EC50H = 7.24 nM;  EC50L = 15.14 μM) subjects. The presence or absence of antipsychotic medication did not influ-
ence the pharmacological parameters.
Conclusions Feasibility of functional evaluation of dopamine receptors in postmortem human brain by conventional  [35S]
GTPγS-binding assays appears to be restricted to signalling through inhibitory  Gi/o proteins. These findings provide functional 
information about brain D2R status in subjects with schizophrenia and do not support the existence of D2R supersensitive 
in this mental disorder.
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D2Low  Low-affinity state of dopamine  D2 receptors
GPCR  G-protein coupled receptor
[35S]GTPγS  Sulfur 35 labelled 
guanosine-5′-O-(γ-thio)-triphosphate
NPA  R(−)-propylnorapomorphine, 
N-propylapomorphine
PET  Positron emission tomography
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Introduction
Schizophrenia is a chronic mental syndrome, characterized 
by a wide range of symptoms that include hallucination, 
delusions, disorganized thinking, anhedonia, apathy and 
cognitive deficits, among others. Despite important efforts, 
the etiopathogenesis of this disorder remains elusive. The 
most extended hypothesis of schizophrenia proposes that 
hyperactivity of dopamine transmission in the mesolim-
bic neurotransmission system is responsible for positive 
symptoms (hallucinations, delusions), whereas a prefrontal 
hypodopaminergia would contribute to negative (alogia, 
anhedonia, abolition) and cognitive symptoms [1]. This 
hypothesis was conceptualized from the seminal work of 
Carlsson and Lindqvist who identified the alterations of 
dopamine turnover induced by antipsychotic drugs [2], 
and the additional evidence that amphetamine, which 
increases monoamine synaptic concentrations, exacerbated 
psychotic symptoms [3]. The subsequent demonstration 
that potency of antipsychotic drugs to block dopamine  D2 
receptors correlates with their effective clinical doses [4] 
provided credibility to the excess of dopaminergic activity 
as an underlying mechanism of psychosis in schizophrenia.
Dopamine receptors are members of the G-protein-
coupled receptor (GPCR) superfamily and conventionally 
subdivided into  D1 and  D2 families. The  D1 family  (D1 and 
 D5 receptors) is coupled to stimulatory  Gs proteins, which 
activate adenylyl cyclase, while the  D2 family  (D2,  D3 and 
 D4 receptors) inhibits adenylyl cyclase activity by inter-
acting with  Gi/o proteins. Alternative effector pathways 
have also been described for dopamine receptor signalling 
[5]. In the central nervous system (CNS), dopamine  D2 
receptors (D2R) are expressed pre- and post-synaptically 
and mainly distributed in striatum, nucleus accumbens and 
olfactory tubercle, with minor expression in the substantia 
nigra, ventral tegmental area, hypothalamus, cortex, amyg-
dala and hippocampus. Dopamine  D1 receptors (D1R) are 
post-synaptic receptors and highly expressed in striatum, 
amygdala, olfactory bulb and frontal cortex [5].
In vivo neuroimaging based on positron emission 
tomography (PET) and single photon emission comput-
erized tomography (SPECT) techniques has been used 
to evaluate the status of D2R and D1R in schizophrenia 
patients. Initial studies in basal ganglia were inconsist-
ent, with some of them reporting increased D2R density 
and others no differences from controls [1, 6]. Elevated 
D2R density was suggested to be a consequence of recep-
tor upregulation after long-term antipsychotic medication 
since drug-naïve patients did not show such PET altera-
tions [7]. In vitro postmortem binding studies corroborated 
the finding of enhanced striatal D2R-binding density in 
schizophrenia [8, 9]. As for D2R, in vivo observations on 
D1R density in prefrontal cortex of drug-naïve schizophre-
nia patients have shown discrepancies [6]. In contrast to 
this earlier focus on postsynaptic D1R and D2R dysregu-
lation, more recent findings point towards a critical role 
for presynaptic dopamine dysfunction in schizophrenia. 
Thus, elevated presynaptic dopamine synthesis capacity 
[10, 11], higher synaptic dopamine concentration [12, 13], 
and amphetamine-induced dopamine release [11, 14] have 
been demonstrated in striatum of subjects with schizo-
phrenia. Conversely, evidence suggests a reduction of 
amphetamine-induced dopamine release in frontal cortex 
of schizophrenia patients [15], indicating a presynaptic 
hypodopaminergia in this brain area [15].
According to the ternary model, GPCRs display two 
interchangeable conformations in equilibrium. The high-
affinity receptor state coupled to heterotrimeric G proteins 
possesses higher affinity for endogenous and exogenous 
agonists, and represents the functional active conforma-
tion. Otherwise, the low-affinity receptor state is uncoupled 
from G proteins and shows preferential affinity for inverse 
agonists. Antagonist drugs do not discriminate between the 
high- and low-affinity states, labelling with similar affinity 
both conformational states. Application of this pharmaco-
logical concept could shed light on the multiple and conflict-
ing results about D2R in schizophrenia. In this context, an 
elevation of D2R in the high-affinity conformation in the 
caudate, putamen and nucleus accumbens of schizophrenia 
subjects has been shown [16]. However, signalling studies to 
assess the functional status of this receptor in this disorder 
are absent.
The first design of the present study sought to evaluate 
the functional status of dopamine-sensitive receptors in 
brain caudate nucleus and frontal cortex of subjects with 
schizophrenia and their matched controls. A basic pharma-
cological characterization of G-protein responses to dopa-
mine receptor activation was initially performed to explore 
the feasibility of the study in both human brain areas. The 
functional coupling of dopamine receptors to G proteins 
was assessed by  [35S]GTPγS-binding assays as previously 
described [17–19]. Assays of  [35S]GTPγS-binding responses 
to the endogenous neurotransmitter dopamine and to selec-
tive D1R and D2R synthetic agonists were performed under 
similar methodological conditions. The method is based 
on the ability of the radiolabelled GTP non-hydrolyzable 
analog called sulfur 35 labelled guanosine-5’-O-(γ-thio)-
triphosphate,  [35S]GTPγS, to specifically bind Gα subunits 
of G proteins. Activation of GPCRs by agonists promotes the 
GDP/GTP exchange and, therefore, facilitates the binding of 
 [35S]GTPγS to the different α subunits of G proteins. Thus, 
the agonist-induced modulation of the  [35S]GTPγS binding 
provides a functional measure of GPCR functionality. This 
assay has been widely used as a functional approach in post-
mortem brain tissue studies, although it has the limitation 
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that does not work equally well for all the G-protein sub-
types [20, 21]. In spite of that, several studies in different 
psychiatric disorders have demonstrated the feasibility of the 
 [35S]GTPγS binding technique to detect altered responses 
of different GPCRs in postmortem brain tissue of affected 
subjects [22–29].
Materials and methods
Human brain samples were obtained at autopsy in the 
Basque Institute of Legal Medicine, Bilbao, Spain, and 
stored at -80ºC in the brain bank facilities of the University 
of the Basque Country until assay. A toxicological screen-
ing on blood at the time of death (detection of antidepres-
sants, antipsychotics, psychotropic drugs and ethanol) was 
performed at the National Institute of Toxicology, Madrid, 
Spain. Collection and use of the samples were developed in 
compliance with Spanish policies of research in postmortem 
brain studies and were approved by the ethical review board 
of the University of the Basque Country.
Specimens of the dorsolateral prefrontal cortex and the 
caudate nucleus head were selected from 17 subjects with 
antemortem diagnosis of schizophrenia according to DSM-
IV and DSM-IVTR criteria, and from 17 matched control 
subjects. Seven additional control subjects were selected to 
perform the initial characterization of  [35S]GTPγS binding 
assays. The schizophrenia subjects were divided into antip-
sychotic-free and antipsychotic-treated according with the 
presence or absence of antipsychotics in blood at the time 
of death. Presence of ethanol and drugs of abuse in control 
subjects was not considered as exclusion criteria due to their 
regular presence among schizophrenia subjects. Schizophre-
nia and control subjects were matched for age, sex, and post-
mortem delay (time interval between death and autopsy). 
All these parameters were not statistically different between 
groups. Demographic characteristics, postmortem delay and 
toxicological information of subjects with schizophrenia and 
individually matched controls are shown in Table 1.
The membrane preparation and the  [35S]GTPγS binding 
assays were performed as previously reported in detail [17, 
18].  P2 membrane fractions (40 μg) were incubated at 30 °C 
for 2 h (1 mM EGTA, 3 mM  MgCl2, 100 mM NaCl, 1 mM 
DTT, 50 μM GDP, 50 mM Tris–HCl at pH 7.4) with 0.5 nM 
 [35S]GTPγS. Increasing concentrations of the endogenous 
neurotransmitter dopamine  (10–10–10–3 M), the selective 
D1R agonist SKF38393  (10–10–10–3 M) or the selective D2R 
agonist N-propylapomorphine (NPA)  (10–10–10–3 M) were 
added to delineate receptor-stimulated  [35S]GTPγS binding 
curves. The pharmacological profile of the targets was tested 
by using the selective D1R antagonist SCH23390 (10 μM) or 
the D2R antagonist haloperidol (10 μM). Basal binding was 
assumed to be the specific  [35S]GTPγS binding in absence of 
agonist. Nonspecific  [35S]GTPγS binding was determined in 
the presence of unlabelled GTPγS (10 μM) and represented 
around 2% of total binding. The reaction was terminated by 
Table 1  Demographic characteristics, postmortem delay, and toxico-
logical information of individual cases of schizophrenia subjects and 
their respective matched controls
F female, M male. The postmortem delay represents the time 
elapsed between death and autopsy. Toxicological results are coded 
as amphetamine (Amp), biperiden (Bip), cannabis (THC), clotia-
pine (Clot), clozapine (Cloz), cocaine and benzoilecgonine (Coc), 
diazepam (Dia), ethanol (OH), haloperidol (Hal), levomepromazine 
(Lmep), lorazepam (Lor), morphine (Mor), nordiazepam (Nor), olan-
zapine (Ola), quetiapine (Quet), sulpiride (Sul)





Case 1 M 21 24 (−)
Control 1 M 21 30 Amp, THC, 
OH
Case 2 M 30 51 (−)
Control 2 M 29 18 (−)
Case 3 M 44 7 Clot, Lmep, 
Nor, Bip
Control 3 M 44 23 (−)
Case 4 M 30 18 Ola
Control 4 M 30 11 THC
Case 5 M 29 6 THC
Control 5 M 29 36 OH
Case 6 M 31 14 Lor
Control 6 M 32 28 Amp, OH
Case 7 M 32 8 Quet, Lor
Control 7 M 32 20 OH
Case 8 M 48 20 (−)
Control 8 M 47 18 Dia
Case 9 M 23 16 Sul
Control 9 M 23 17 (−)
Case 10 M 35 3 Quet, Nor
Control 10 M 36 23 (−)
Case 11 F 30 28 Hal,
Control 11 F 29 31 (−)
Case12 M 31 11 (−)
Control 12 M 31 13 OH
Case 13 M 33 14 Dia
Control 13 M 33 4 (-)
Case14 M 45 3 Nor
Control 14 M 44 21 (−)
Case 15 F 37 58 Mor, Dia
Control 15 F 36 38 Mor, Dia, Coc
Case 16 M 46 22 Bip
Control 16 M 46 24 (−)
Case 17 M 35 11 Cloz, Nor
Control 17 M 36 18 Coc, OH
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rapid vacuum through Whatman GF/C glass fibre filters and 
the remaining bound radioactivity was measured by liquid 
scintillation counting. Specific  [35S]GTPγS binding values 
were calculated subtracting nonspecific-binding values. 
Then, these specific values were transformed to percentage 
of basal binding  ([35S]GTPγS binding values in the absence 
of any exogenous drug) which was considered as 0%. Results 
are represented as increases of percentage over the respec-
tive basal values.
Individual concentration–response curves of the ago-
nist-stimulated  [35S]GTPγS binding assays were analyzed 
by non-linear regression using GraphPad Prism software. 
Statistical selection between monophasic or biphasic curve 
models was made by the extrasum-of-square F test, using 
GraphPad Prism. The maximal stimulation expressed as 
percentage over the corresponding basal binding  ([35S]
GTPγS binding in the absence of any exogenous ligand) and 
the concentration of the agonist that elicited half-maximal 
effect  (EC50) were obtained.  EC50 values were normalized 
as log  EC50 (-pEC50) values before parametric comparisons. 
Student’s t test was used to compare individual values of 
pharmacological parameters between schizophrenia and 
control groups. On the other hand, non-linear regression 
co-analysis of all individual curves of each group was con-
ducted to further compare schizophrenia vs. control groups, 
and antipsychotic-free or antipsychotic-treated subjects vs. 
corresponding matched controls. The analysis that permit-
ted one or more of the parameters to be shared without a 
significant increase in the residual variance was taken as the 
best fit [30]. Results are expressed as mean ± standard error 
(SE) and the level of statistical significance was chosen as 
p = 0.05.
Sulfur 35 labelled guanosine-5’-O-(γ-thio)-triphosphate 
 ([35S]GTPγS; 1250  Ci/mmol) was purchased from 
PerkinElmer Life Science (Maanstraat, Germany). 
Dopamine HCl, GDP, GTPγS, haloperidol and R(−)-
propylnorapomorphine HCl (also termed N-propylapomor-
phine) were obtained from Sigma Aldrich (St. Louis, USA). 
R( +)-SCH23390 HBr, ( ±)-SKF38393 HBr and MDL11939 
were purchased from Tocris Bioscience (Bristol, UK). All 
other chemical reagents were of the highest analytical qual-
ity and were obtained from Merck (Darmstadt, Germany) 
or Sigma-Aldrich.
Results
The concentration–response curves of  [35S]GTPγS bind-
ing for dopamine in caudate head membrane preparations 
displayed monophasic stimulation curves with an estimated 
 EC50 = 5.57 μM (Table 2). The selective D1R antagonist 
SCH23390 (10 μM) did not modify the stimulation param-
eters (t10 = 2.16, p = 0.06), whereas the D2R antagonist 
haloperidol (10 μM) promoted a right-shift of the curves 
(t9 = 6.43, p = 0.0001) that did not reach a clear asymptote 
(Table 2). These findings were compatible with a main 
dopamine-induced stimulation of G proteins that could be 
mediated by D2R (Fig. 1A).
The concentration response curves to the selective 
D1R agonist SKF38393 in caudate were also monophasic 
with low stimulatory effect and estimated  EC50 = 3.46 μM 
(Table 2). The selective D1R antagonist SCH23390 (10 μM) 
was not able to displace the stimulations induced by 
SKF38393 in this area (t6 = 0.42, p = 0.69), which suggests 
that this effect was not mediated by D1R (Fig. 1B).
When the selective D2R agonist NPA was used to 
stimulate the  [35S]GTPγS binding, biphasic concentra-
tion–response curves [F(2,103)  = 20.17, p < 0.0001 vs. 
Table 2  Pharmacological 
parameters of the 
concentration–response 
curves of  [35S]GTPγS binding 
stimulation induced by 
different agonists in absence 
and presence of selective 
antagonists in human caudate
Values are means ± SE of independent experiments performed in tissue homogenates from 4–7 different 
control subjects.  logEC50 values are log normalized values of the agonist concentration that elicited half-
maximal effect obtained from concentration–response curves.  Emax is the maximal % stimulation of  [35S]
GTPγS binding over basal values. H and L represents the high-, and low-affinity fractions of the curves, 
respectively. N/A: not applicable due to the existence of a monophasic curve model. aEmax for dopa-
mine + haloperidol represents an approximate estimation due to absence of asymptotic values
log  EC50H log  EC50L Emax
(%)
Fraction H (%)
Dopamine − 5.25 ± 0.10 – 29 ± 1 N/A
Dopamine + haloperidol − 4.01 ± 0.19 – 12 ±  1a N/A
Dopamine + SCH23390 − 4.85 ± 0.17 – 30 ± 2 N/A
SKF38393 − 5.46 ± 0.23 – 14 ± 1 N/A
SKF38393 + SCH23390 − 5.63 ± 0.33 – 12 ± 1 N/A
N-propylapomorphine (NPA) − 8.10 ± 0.28 − 4.93 ± 0.23 38 ± 4 56 ± 11
NPA + haloperidol – − 5.25 ± 0.14 25 ± 2 N/A
NPA + SCH23390 − 7.39 ± 0.26 – 21 ± 1 N/A
NPA + MDL11939 − 8.03 ± 0.21 − 4.76 ± 0.30 37 ± 3 54 ± 8
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monophasic model] were obtained with  EC50 values of 
6.31 nM and 85.11 μM (Table 2). The NPA stimulations 
were also carried out in the presence of SCH23390 (10 μM) 
and, then, monophasic curves corresponding to the high-
potency component of NPA stimulation were obtained with 
a non-significant slight displacement of the curve to the right 
 (EC50 = 41 nM) (t10 = 1.78, p = 0.11) (Table 2). Monophasic 
curves were also obtained in the presence of haloperidol 
(10 μM), but this time potency values mirrored the low-
potency component of NPA stimulation  (EC50 = 5.59 μM) 
(t10 = 1.07, p = 0.31), whereas the high-potency component 
was abolished (t10 = 6.84, p < 0.0001) (Table  2). These 
results indicated that the high-potency component of the 
 [35S]GTPγS binding stimulation by NPA was compatible 
with D2R (Fig. 1C). The low-potency component of NPA 
stimulation could apparently be sensitive to SCH23390, 
suggesting the presence of D1R-mediated activity but other 
possibilities should also be considered due to the elevated 
concentration of SCH23390 used.
Since SCH23390 displays important affinity (9.3–30 nM) 
[31, 32] and efficacy [33] on serotonin 5-HT2 receptors, the 
hypothesis that the low-potency component of NPA stimula-
tion in caudate represents a serotonin 5-HT2A receptor inter-
action was tested. The selective 5-HT2A receptor antagonist 
MDL11939 (1 μM) did not modify the biphasic stimulatory 
curves promoted by NPA on  [35S]GTPγS binding (t8 = 0.15, 
p = 0.88 for the NPA high potency; t8 = 0.42, p = 0.69 for the 
NPA low potency), which dismissed the idea (Table 2 and 
Supplementary Fig. 1).
In postmortem human frontal cortex membrane prepara-
tions, the concentration–response curves of dopamine on 




















































































Fig. 1  Concentration response curves of the  [35S]GTPγS binding 
stimulation by increasing concentrations  (10–10-10–3 M, 13 concentra-
tions) of A dopamine (DA), B the selective D1R agonist SKF38393 
and C the selective D2R agonist N- propylapomorphine (NPA) in 
absence and presence of the D1R antagonist SCH23390 (10  μM) 
or the D2R antagonist haloperidol (10  μM). Experiments were per-
formed in human caudate of 4–7 different control subjects. Points are 
mean ± standard error of the mean and represent the increase (in per-
centage) over respective basal values. BB represents the basal binding 
in absence of agonist
Table 3  Pharmacological parameters of the concentration–response 
curves of  [35S]GTPγS binding stimulation induced by different ago-
nists in absence and presence of selective antagonists in human fron-
tal cortex
Values are means ± SE of independent experiments performed in tis-
sue homogenates from 3–7 different control subjects.  logEC50 values 
are log normalized values of the agonist concentration that elicited 
half-maximal effect obtained from concentration–response curves. 
Emax is the maximal % stimulation of  [35S]GTPγS binding over basal 
values
log  EC50 Emax
(%)
Dopamine − 4.52 ± 0.10 85 ± 4
Dopamine + haloperidol − 4.56 ± 0.12 90 ± 5
Dopamine + SCH23390 − 4.30 ± 0.10 85 ± 4
SKF38393 − 5.13 ± 0.27 10 ± 1
SKF38393 + SCH23390 − 5.38 ± 0.39 11 ± 2
N-propylapomorphine (NPA) − 5.22 ± 0.10 51 ± 2
NPA + haloperidol − 5.47 ± 0.11 54 ± 2
NPA + SCH23390 − 5.54 ± 0.10 54 ± 3
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estimated  EC50 = 30.4 μM (Table 3). Neither SCH23390 
(10  μM) (t5 = 1.52, p = 0.19) nor haloperidol (10  μM) 
(t8 = 0.24, p = 0.82) modified the dopamine-induced stimu-
lation curves (Table 3). Compared with values in caudate, 
 EC50 values of dopamine curves were lower (t10 = 1.78, 
p = 0.11) and maximal effects were higher (t10 = 11.5, 
p < 0.0001) in frontal cortex. These findings were compat-
ible with a dopamine activity on G proteins that was not 
mediated by either D1R or D2R (Fig. 2A).
SKF38393 stimulations of  [35S]GTPγS binding in fron-
tal cortex were very low with an estimated  EC50 = 7.41 μM 
(Table 3). SCH23390 (10 μM) did not modified SKF38393 
curves in this brain area (t5 = 0.55, p = 0.61). This fact con-
tributed to reject the possibility of D1R involvement in the 
effect of SKF38393 (Fig. 2B).
In frontal cortex, NPA stimulation curves of the  [35S]
GTPγS binding were monophasic with  EC50 value of 
5.99 μM (Table 3). The D1R antagonist SCH23390 (10 μM) 
did not modify NPA curves (t7 = 2.23, p = 0.06) (Table 3). In 
the same way, NPA-mediated stimulation was insensitive to 
haloperidol (10 μM) (t8 = 1.64, p = 0.14) (Table 3). The  EC50 
values of NPA in the frontal cortex were in the micromolar 
range, which corresponds to values of the low-potency com-
ponent of NPA curves in caudate (Fig. 2C). These results 
suggested that the  [35S]GTPγS-binding stimulation by NPA 
in frontal cortex did not represent activity on D1R or D2R, 
and could involve alternative GPCRs (Fig. 2C), as shown 
with dopamine (see Fig. 2A).
After this pharmacological characterization of dopa-
mine receptor targets involved in the functional responses 
induced by dopamine, SKF38393 and NPA, and to assess 
the status of caudate D2R in schizophrenia, concentra-
tion–response curves for NPA were performed in membrane 
homogenates from 17 subjects with schizophrenia and 17 
individually matched controls (Table 1). Basal activity of 
 [35S]GTPγS binding was not different between schizophre-
nia (1,952 ± 121 fmol/mg protein) and control (1,755 ± 80 
fmol/mg protein) groups (t32 = 1.34, p = 0.19). NPA stimu-
latory curves better adjusted to a biphasic concentration-
effect model in both groups. The co-analysis of the curves 
demonstrated their similarity [F(4,366) = 0.178; p = 0.95]. 
 EC50 values (t32 = 0.06, p = 0.96 for the NPA high-potency; 
t32 = 0.55, p = 0.59 for the NPA low-potency), maximal stim-
ulatory effects (t32 = 0.35, p = 0.73), and proportion of high/
low components (t32 = 0.55, p = 0.59) did not differ between 
schizophrenia and control curves (Table 4; Fig. 3).
The one-to-one matching design of the study allowed 
us to separately compare antipsychotic-free (n = 10) and 
antipsychotic-treated (n = 7) schizophrenia subjects with 
their respective controls. The NPA stimulation curve of 
 [35S]GTPγS binding in antipsychotic-free subjects was 
not different to that in controls [F(4,276) = 2.02, p = 0.09]. 




















































































Fig. 2  Concentration response curves of the  [35S]GTPγS binding 
stimulation by increasing concentrations  (10–10-10–3 M, 13 concentra-
tions) of A dopamine (DA), B the selective D1R agonist SKF38393 
and C the selective D2R agonist N- propylapomorphine (NPA) in 
absence and presence of the D1R antagonist SCH23390 (10  μM) 
or the D2R antagonist haloperidol (10  μM). Experiments were per-
formed in human frontal cortex of 3–7 different control subjects. 
Points are mean ± standard error of the mean and represent the 
increase (in percentage) over respective basal values. BB represents 
the basal binding in absence of agonist
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group  (EC50H = 8.32 nM,  EC50L = 13.2 μM) were in simi-
lar range to those in matched controls  (EC50H = 4.79 nM, 
 EC50L = 24.6 μM). In a similar way, antipsychotic-treated 
schizophrenia subjects showed NPA-mediated  [35S]GTPγS-
binding stimulations that did not differ from that of matched 
controls (F[4,172] = 0.68, p = 0.61).  EC50 values in antipsy-
chotic-treated subjects  (EC50H = 3.80 nM,  EC50L = 1.48 μM) 
were similar to  EC50 values in corresponding controls 
 (EC50H = 5.75 nM,  EC50L = 2.13 μM).
Discussion
The present study focused on G-protein activation by D1R 
and D2R agonists in membrane homogenates obtained from 
postmortem human caudate and prefrontal cortex. As func-
tional data for dopamine receptors in human brain are scarce 
in the literature, basic characterization of  [35S]GTPγS bind-
ing responses to D1R and D2R activation by dopamine and 
subtype selective agonists was initially performed to explore 
the feasibility of the study in both human brain areas. After-
wards, the potential dysfunction of D2R coupling to G pro-
teins in caudate of schizophrenia subjects was assessed. 
Caudate head was selected due to the important activation 
by D2R agonist [34] and the D2R density alterations in basal 
ganglia previously described in schizophrenia [1, 6, 7]. The 
dorsolateral prefrontal cortex was explored, because it con-
stitutes a critical area in schizophrenia where D1R show 
higher expression than D2R [5].
Previous  [35S]GTPγS-binding assays in rodent striatal 
membranes generally described the presence of D2R [35–37] 
in this area. Thus, stimulatory responses were obtained for 
quinpirole  (pEC50 = 5.4–5.8), pergolide  (pEC50 = 6.5–7.7) 
and NPA  (pEC50 = 7.8–8.4), among other selective D2R 
agonists [35–37]. In contrast, the preferential D1R agonists 
SKF38393  (pEC50 = 3.2) and SKF81297 were almost inac-
tive and, when small efficacy was displayed, insensitivity to 
the selective D1R antagonist SCH23390 was observed [37]. 
In rat striatum, concentration–response  [35S]GTPγS-binding 
curves to the endogenous agonist dopamine revealed  EC50 
values in the micromolar range  (pEC50 = 5.2–5.5). In these 
studies, the dopamine-induced stimulations were inhibited 
by the D2R antagonists haloperidol  (pKb = 9.4–8.1) and 
raclopride ((pKb = 9.0–8.2) but not by the D1R antagonist 
SCH23390 both in striatal membranes [35–37] and in tissue 
sections [38].
In postmortem human brain tissue, previous autoradio-
graphic mapping of  [35S]GTPγS binding response to sin-
gle concentrations of dopamine or selective D1R and D2R 
agonists demonstrated an anatomical distribution of the 
functional activation with the highest effects (24% approxi-
mately) in dorsal caudate [34]. Present findings in the same 
brain area indicated a D2R pharmacological profile that 
agrees with previous data in rodents. Dopamine stimulates 
 [35S]GTPγS binding with  EC50 values in the micromolar 
range and the curves are considerably shifted to the right by 
the D2R antagonist haloperidol but not by the D1R antago-
nist SCH23390. NPA evoked a biphasic stimulation of  [35S]
GTPγS binding in human caudate, and a similar profile com-
patible with D2R was observed for the high-potency compo-
nent of the curves. Furthermore, the D1R agonist SKF38393 
induced a lower  [35S]GTPγS-binding stimulation that was 
Table 4  Pharmacological parameters of the concentration–response curves of  [35S]GTPγS binding stimulation induced by N-propylapomorphine 
(NPA) in human caudate of subjects with schizophrenia and controls
Values are means ± SE of independent experiments performed in tissue homogenates from 17 subjects in each group.  logEC50 values are log nor-
malized values of the agonist concentration that elicited half-maximal effect obtained from concentration–response curves.  Emax is the maximal 
% stimulation of  [35S]GTPγS binding over basal values. H and L represents the high-, and low-affinity fractions of the curves, respectively
log  EC50H log  EC50L Emax
(%)
Fraction H (%)
Schizophrenia (n = 17) − 8.11 ± 0.40 − 5.17 ± 0.49 22 ± 2 56 ± 10
Control (n = 17) − 8.14 ± 0.37 − 4.82 ± 0.36 23 ± 2 49 ± 8


























Fig. 3  Concentration response curves of the  [35S]GTPγS binding 
stimulation by increasing concentrations  (10–10-10–3 M, 13 concentra-
tions) of the selective D2R agonist N-propylapomorphine (NPA) in 
caudate of subjects with schizophrenia (n = 17) and matched controls 
(n = 17). Points are mean ± standard error of the mean and represent 
the increase (in percentage) over respective basal values. BB repre-
sents the basal binding in absence of agonist
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insensitive to the D1R antagonist SCH23390. Therefore, the 
present results suggest a selective targeting of D2R-mediated 
activation of G proteins in human caudate. Several limita-
tions must be acknowledged, including the absence of a full 
characterization of dopamine, SKF38393 and NPA targets. 
Both haloperidol and SCH23390 were used at high and non-
selective D2R and D1R affinity concentrations, respectively. 
This may have led to antagonism over other GPCRs, espe-
cially when dopamine was used as agonist. It should also be 
recognized that maximal stimulatory effects observed herein 
are lower than those reported in rodents [35, 37], although 
similar to values in human caudate sections [34]. Efficacy 
of agonist-stimulated  [35S]GTPγS binding is very sensitive 
to experimental conditions and mainly depends on GDP and 
NaCl concentrations employed [17, 19, 35–37]. Therefore, 
discrepancies in this parameter between studies may reflect 
particular incubation conditions of the different assays and/
or differences between human and rodents.
In human frontal cortex, dopamine and NPA stimulation 
of  [35S]GTPγS binding displayed monophasic curves with 
lower  EC50 values and higher maximal stimulations than 
in caudate. The presence of haloperidol or SCH23390 did 
not attenuated the agonist-induced responses. Moreover, 
SKF38393 promoted a small stimulation with similar pro-
file to caudate and that, again, was insensitive to SCH23390. 
Hence, the findings substantially reflect the role in the 
response of an undetermined GPCR different from D1R 
and D2R. These data are consistent with earlier findings in 
the same human brain area where dopamine elicited a low-
potency response  (pEC50 = 4.24) insensitive to both D1R 
and D2R antagonists but sensitive to the α2-adrenoceptor 
antagonist RX821002 (2-methoxyidazoxan) [19].
Besides coupling to G proteins that promote adenylyl 
cyclase activation or inhibition, it has been suggested the 
existence of a D1-like receptor that activates phospholi-
pase C (PLC) and thus stimulates the production of dia-
cylglycerol and inositol trisphosphate. The effector sys-
tem for this non-canonical response is the  Gq/11-protein 
subtype [39]. The D1-like-mediated activation of  Gq/11 
proteins has been found in rat cortex and striatum, among 
other brain areas [33, 40, 41]. The pharmacological evi-
dence for the existence of this D1-like receptor is sup-
ported by the dopamine activity on this pathway, the func-
tional agonist bias role of the D1R compound SKF83959 
towards PLC signalling [42], and the antagonism elicited 
by SCH23390. Furthermore, it has been argued that this 
response would occur via coactivation of a D1R-D2R het-
erodimer functionally active in brain [43]. However, the 
existence of the D1R–D2R heterodimer is controversial 
[44] and the pharmacological activity of SKF83959 and 
related benzazepines as SKF38393 and SCH23390 seems 
to represent off-target effects due to their added affinity 
for serotonin 5-HT2A/2C receptors and/or α2-adrenoceptors 
[31–33, 45]. According to this evidence, it is conceivable 
that  [35S]GTPγS-binding stimulation by dopamine, NPA 
and SKF38393 observed in human frontal cortex in the 
present study represents activation of GPCRs unrelated 
to D1R and D2R. The exact pharmacological identity of 
this stimulation remains to be elucidated but is outside the 
scope of the present study.
In relation to the low-potency component of NPA stimu-
lation in caudate, the present results discard a D1R-medi-
ated component. The dopamine- and SKF38393-mediated 
stimulations of  [35S]GTPγS binding were insensitive to 
SCH23390, which make this possibility unlikely. On the 
other hand, although there is no evidence in the literature 
of NPA affinity for 5-HT2A receptors, the failure of NPA to 
detect this second fraction in the presence of SCH23390 and 
the above-mentioned affinity of this compound for 5-HT2A 
receptors [32], led us to test whether the low-potency com-
ponent of NPA represented activation of 5-HT2A receptors. 
For this purpose, the selective 5- HT2A receptor antagonist 
MDL11939 was added to the NPA-mediated stimulation 
assay. MDL11939 did not modify the  [35S]GTPγS-binding 
response to NPA in caudate, confirming the lack of 5-HT2A 
receptor involvement in the biphasic stimulation.
[35S]GTPγS binding technique represents a functional 
approach that has been successfully applied to the detec-
tion of receptor-dependent G-protein activation by differ-
ent GPCRs even in postmortem human brain tissue [17, 
19, 46]. Guanine nucleotide exchange represents the first 
measurable step in the receptor-initiated signal transduc-
tion pathways, helping to avoid cross-talk interactions that 
affect the response. One limitation of both the conventional 
 [35S]GTPγS binding assay using filtration techniques and 
functional autoradiography assays is the fact that appear to 
be restricted for detection of activation responses involving 
inhibitory G protein subtypes [21, 47–49]. Functional activa-
tion of other G proteins (e.g.,  Gs/olf and  Gq/11) in brain seems 
to be undetectable with this approaches [21]. The higher fea-
sibility of detection of  [35S]GTPγS binding to  Gi/o proteins 
is attributed to two main reasons: (a) the relative abundance 
of  Gi and specially  Go proteins in brain over other families 
[50], and (b) their higher rates of nucleotide exchange [47, 
48]. Regarding dopamine receptors, D1R family is preferen-
tially coupled to stimulatory  Gs proteins, whereas D2R fam-
ily mediates activation of  Gi/o proteins [5]. In this context, 
and although D1R predominate over D2R family in frontal 
cortex, the pharmacological profile of G- protein activation 
obtained in the present study for dopamine and D1R selec-
tive agonist in this area does not correspond to D1R and 
would be considered more probably as an off-target phar-
macological effect. This fact also indicates that the meth-
odological conditions for conventional  [35S]GTPγS-binding 
activation herein used, are not the most appropriate to detect 
G-protein activation by D1Rs.
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In summary, the findings of the present work confirm that 
feasibility to quantify the dopamine receptor-mediated acti-
vation of G proteins in brain is limited to D2R family. The 
study provides suitable methodological conditions to assess 
the functional status of D2R in caudate from subjects with 
schizophrenia. Alternative methods based on  [35S]GTPγS-
binding stimulations combined with immunoprecipitation 
assays by selective antibodies for the different G proteins 
could help to improve detection of D1R family functional 
activity in human brain [51].
The dopamine hypothesis of schizophrenia is based on 
the idea of an increased dopamine neurotransmission in 
brain. This enhanced activity may be mediated by increased 
neurotransmitter synthesis [10, 11], release [11, 14], synap-
tic concentrations [12, 13] and/or the existence of supersen-
sitive postsynaptic dopamine receptors, especially D2R, the 
common target of antipsychotics. In schizophrenia patients, 
in vivo neuroimaging studies by PET and SPECT have 
reported controversial results in relation to D2R density. 
Early observations provided evidence for elevated binding 
capacity that argued in favour of the striatal hyperdopamin-
ergic hypothesis. In contrast, further studies in drug naïve 
patients showed equivalent density to controls [1, 6, 16]. 
Discrepancies seem to be due to the low selectivity of first 
radiotracers  ([11C]NSMP) compared to the most recents 
 ([11C]raclopride and  [123I]IBZM), and to the confounding 
effect of antipsychotic treatment [6]. Postmortem radioli-
gand-binding studies have shown enhanced D2R density in 
caudate nucleus [8, 52], and the existence of heterogeneous 
subject populations, despite the shared diagnosis of schizo-
phrenia [8, 9]. A large body of evidence describes supersen-
sitivity of D2R as a consequence of effective antipsychotic 
treatment [53, 54]. As drug-free populations are difficult to 
obtain for postmortem studies, most studies do not include 
them and, in consequence, increased density of striatal D2R 
is the most reported finding in the literature.
Nevertheless, Seeman updated the dopaminergic hypoth-
esis and proposed that schizophrenia is associated with stri-
atal D2R supersensitivity due to disequilibrium between the 
high- (D2High) and the low- (D2Low) affinity conforma-
tions of the receptor [7, 16]. The term D2High represents the 
functional state of the receptor, which shows relative selec-
tivity for agonist drugs and is coupled to G proteins. Accord-
ing to the hypothesis, an imbalance of D2R towards D2High 
might be present in schizophrenia, leading to G-protein over 
activation. In this context, the use of agonist radioligands for 
in vivo and in vitro studies of D2R in schizophrenia would 
offer advantage over antagonists, which do not discriminate 
between D2High and D2Low conformations. Consistent 
with this interpretation, antibody immunodetection of D2R, 
that do not discriminate among receptor conformations, in 
caudate of schizophrenia subjects with and without residual 
antipsychotics showed similar protein expression to controls 
[55]. Equivalent results were found in human frontal cortex 
[56]. In this context, the  [35S]GTPγS-binding stimulation 
by selective D2R agonists would be useful for detecting 
specific alterations of the functional receptor conformation 
(D2High) associated to schizophrenia. The current study 
describes that assessment of striatal  [35S]GTPγS-binding 
response to NPA displays overlapped curves in schizophre-
nia and control groups. This finding suggests the absence of 
striatal D2R hyperactivity in subjects with schizophrenia, 
at least in their coupling to  Gi/o proteins. However, dysfunc-
tions in alternative G-protein-independent D2R signalling 
pathways cannot be discarded [57]. In contrast to this result 
in brain, olfactory neuroepithelial cells from patients with 
schizophrenia displayed enhanced  [35S]GTPγS binding to 
 Gs/olf and  Gi/o proteins in response to a single concentration 
of dopamine [58]. In absence of pharmacological charac-
terization, this change in olfactory cells does not directly 
reflect selective D2R dysfunction and might be influenced 
by the antipsychotic treatment present in six out of the ten 
patients evaluated.
The presence or absence of antipsychotic treatment is a 
condition that influences D2R analysis. As previously men-
tioned, long-term antipsychotic administration upregulates 
D2R density and function [52–54]. In the present study, 
and to unmask a possible effect of antipsychotic treatment, 
independent and well-matched groups of antipsychotic-free 
and antipsychotic-treated subjects were defined and inde-
pendently analyzed vs. respective control groups. Absence 
of changes in NPA activation of  [35S]GTPγS binding was 
observed regardless presence or absence of antipsychotic 
treatment at death.
In summary, the present study provides functional infor-
mation related to D2R status in postmortem brain of subjects 
with schizophrenia. The findings do not support the exist-
ence of supersensitive D2R alterations underlying hyperac-
tive dopaminergic neurotransmission as a key feature of this 
mental disorder. Alternative formulations for the dopaminer-
gic hypothesis of schizophrenia warrants further exploration.
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